Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Crown Castle International Corp (CCI) vs 10X Genomics Inc (TXG) Price & Performance

Crown Castle International CorpTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

Crown Castle International Corp vs 10X Genomics Inc — how do they compare? Crown Castle International Corp trades at $73.79 (market cap $31.32B), while 10X Genomics Inc trades at $58.54 (market cap $7.64B). The key difference: Crown Castle International Corp is far larger — about 4.1× 10X Genomics Inc's market cap, and Crown Castle International Corp pays a 5.77% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.

CCITXG
Market Cap
$31.32B$7.64B
Sector
Real EstateHealth
52-Week High
$103.79$58.57
52-Week Low
$73.61$11.34
Enterprise Value
$53.68B$7.17B
Dividend Yield
5.77%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Crown Castle International Corp

Crown Castle (CCI) trades at $75.59, up 0.89% on the day, but technical indicators signal a bearish trend with the stock near recent lows. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, while revenue has declined from $7.0B in 2023 to $4.26B in 2025. Analyst consensus is split evenly between Buy and Hold with a $95.29 price target, suggesting potential upside. Recent news highlights strategic shifts, including the sale of its fiber business and a focus on U.S. tower operations.

The outlook for CCI hinges on execution of its pure-play tower strategy amid high debt levels and competitive pressures. Investment appeal lies in its 5.5% dividend yield and discounted valuation, but risks include declining revenue, negative shareholder equity, and sensitivity to interest rates. Wall Street sees value if operational improvements materialize.

10X Genomics Inc

TXG is trading at $52.03, up 14.1% in the past 24 hours, reflecting strong momentum. The stock exhibits a bullish technical signal with moving averages supporting upward trends, while RSI levels suggest mild overbought conditions. Fundamentally, the company reported Q2 2026 revenue of $151 million, beating estimates, and has shown consistent earnings beats in recent quarters. Recent news highlights collaborations with Cleveland Clinic and the acquisition of Proteintech Genomics, expanding its multiomics capabilities and reinforcing growth prospects.

The outlook for TXG is cautiously optimistic, driven by earnings outperformance and strategic expansions, but risks include persistent net losses and high valuation multiples. Analyst consensus is mixed with a $46 price target, indicating potential downside from current levels. Investors should weigh revenue growth against profitability challenges and monitor execution on new initiatives for sustained upside.

Returns comparison

Trailing returns across standard periods

About Crown Castle International Corp

Crown Castle International owns and leases roughly 40,000 cell towers in the United States. It also owns more than 85,000 route miles of fiber. It leases space on its towers to wireless service providers, which install equipment on the towers to support their wireless networks. The company's fiber is primarily leased by wireless service providers to set up small-cell network infrastructure and by enterprises for their internal connection needs. Crown Castle's towers and fiber are predominantly located in the largest U.S. cities. The company has a very concentrated customer base, with more than 70% of its revenue coming from the big three U.S. mobile carriers. Crown Castle operates as a real estate investment trust.

Read more on CCI

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG